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ABSTRACT

Arsenic contamination of drinking water is a real public health problem in certain areas
of South-East Asia where chronic exposure has been correlated to higher rates of lung, skin,
bladder, kidney, and liver cancer. Although arsenic carcinogenicity is well established, the
mechanism by which it induces cancer is poorly understood. Recent evidence suggests that
oxidative stress could be a possible mechanism for the carcinogenic effects of arsenic. Selenium,
in the form of selenocysteine, is necessary for the activity of several enzymes with a role in the
defense against reactive oxygen species (ROS), primarily thioredoxin reductases (TrxR) and
glutathione peroxidases (Gpx). One of the key enzymes in the incorporation of Se into
selenoproteins is selenophosphate synthetase (SPS). SPS catalyzes the activation of Se to
selenophosphate, and is the first step in the pathway of selenoprotein biosynthesis. SPS contains
a conserved vicinal dithiol motif (CXC) within a region of amino acids that have been predicted
to be a selenium binding site. Our hypothesis is that arsenite inhibits new selenoprotein
synthesis, thus indirectly increasing the level of ROS.
In this study we have developed a spectrophotometric assay for SPS. Using this assay, we
have determined that arsenite inhibits SPS activity. Kinetic analysis of this inhibition showed
that arsenite, a trivalent form of arsenic, acts as a competitive inhibitor with the substrate, sodium
selenide. This inhibition of SPS could represent a potential molecular mechanism for oxidative
stress induced upon arsenite treatment of human cell lines in culture. To further study the effects
of trivalent arsenicals at a cellular level we decided to use a human keratinocyte cell line, HaCaT
as a cell culture model. Our study showed that although arsenite does not alter cell proliferation
iii

or protein synthesis, it specifically inhibits new selenoprotein synthesis. However, short term or
long term exposure of HaCaT cells to arsenite failed to result in changes to Gpx and TrxR levels.
Since the radioisotope selenium used in labeling studies is selenite, these results indicate
that an alternate source of selenium may bypass the inhibitory effects of arsenite. Future studies
will focus on studying the effects of arsenicals on keratinocytes cultured in a defined medium
allowing a better control of the selenium source.
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW

1.1- Importance of selenium
The metalloid selenium exists naturally in organic (e.g. selenomethionine,
selenocysteine) and in inorganic forms (e.g. selenite, selenate, selenide) (Birringer M.,
2002). Selenium compounds need to be metabolized into an inorganic precursor, selenide
(NaHSe), before being inserted into proteins as the 21st amino acid selenocysteine that is
essential for the catalytic function of selenoenzymes (Carlson B.A., 2004). Selenium is
required in several mammalian enzymes with roles in defense against reactive oxygen
species. These include thioredoxin reductase (TrxR), several isoforms of glutathione
peroxidase (Gpx) and a selenium-dependent form of methionine sulfoxide reductase
(SelR) (Tamura T., 1996, Arner, E. S., 2000, Lee S. R. et al., 2000, Flohe, L. et al., 1973,
Brigelius-Flohe, R., 1999, Chambers, I. et al., 1986, Kryukov, G. V. et al., 2002). In a
recent article, using a computational approach, the authors (Kryukov, G.V. et al., 2003)
have shown that 25 genes encoding selenoproteins reside in the sequenced human
genome (Table 1). All selenoproteins with known enzymatic functions contain
selenocysteine in their catalytic center. Selenoproteins incorporate SeCys
cotranslationnally into the polypeptide chain by a complex mechanism (Low, S.C., 1996)
that was only recently elucidated in mammalian system.
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Table 1: Mammalian Selenoproteins

Selenoprotein

Common abbreviations

Key references

Glutathione peroxidase

GPx

Cytosolic or classical GPx

cGPx, GPx-1

Mills G.C. 1957

Phospholipid hydroperoxide GPx

PHGPx, GPx-4

Ursini F. 1982

Plasma GPx

pGPx, GPx-3

Takahashi K. 1987

Gastrointestinal GPx

GI-GPx, GPx-GI, GPx-2

Chu F-F. 1993

50-deiodinase, type I

50DI

Behne 1990, Arthur 1990

50-deiodinase, type II

50DII

Davey J.C. 1995

5-deiodinase, type III

5-DIII

Croteau W. 1995

Thioredoxin reductase

TR

Tamura T. 1996

Mitochondrial thioredoxin reductase

TR-2

Lee 1999, Watabe 1999,
Miranda-Vizuete 1999

Thioredoxin reductase homologs

SelZf1, SelZf2

Lescure A. 1999

Iodothyronine deiodinases

Thioredoxin reductases

Selenophosphate synthetase-2

Guimaraes M.J. 1996

15-kDa selenoprotein (T cells)

Gladyshev V.N. 1998

Selenoprotein P

SelP

Motsenbocker, M.A. 1984

Selenoprotein W

SelW

Vendeland S.C. 1995

Selenoprotein R

SelR

Kryukov G.V. 1999

Selenoprotein T

SelT

Kryukov G.V. 1999

Selenoprotein X

SelX

Lescure A. 1999

Selenoprotein N

SelN

Lescure A. 1999
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1.2- Selenoprotein biosynthesis

The process by which selenocysteine is inserted via translation of a UGA codon
(normally a stop codon) is well described in Escherichia coli (Bock, A., 1991, Leinfelder,
W. et al., 1990), and is currently being characterized in mammals (Berry, M. J. et al.,
1997, Berry, M. J. et al., 2002). A specific tRNA is first loaded with serine, and then
transformed into selenocysteyl-tRNA using selenophosphate as the activated Se donor.
The common UGA stop codon is recoded by SelB, a translation factor in the presence of
a SeCys-charged tRNA and a 3’ untranslated region (SECIS) (Figure 1) (Forchhammer,
K., et al., 1990, Forster C. et al., 1990).
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Figure 1: Nucleotide sequence of tRNASec from a eukaryotic source. Bovine liver
tRNASec (Hatfield D., 1985) containing an esterified serine is converted to selenocysteyltRNASec (Lee B.J. et al., 1989).

Similar to the bacterial system, the coordination of the synthesis of specific
selenocysteine-charged tRNA, elongation factors, and a consensus sequence allows tight
post-transcriptional regulation of selenoprotein biosynthesis by Se in mammals (Flohe L.
et al., 1997). The consensus sequence in a stem-loop RNA structure is located in the 3’
untranslated region (UTR) of the mRNA and known as a SECIS element for SeCys
4

insertion sequence (Kryukov, G. V., 1999). This regulation and specificity is needed in
all biological systems that express selenoproteins in order to prevent read-through of
normal stop codons and non-specific incorporation of selenium into sulfur-containing
amino acids and enzyme cofactors.

1.3- Selenium deficiency

In mammals, when the Se supply is limited, the selenoproteins are individually
synthesized based on their most essential functions (Behne, D., Kyriakopoulos, A., 1993).
Several studies demonstrated that the mRNA levels of the selenoproteins fluctuate
differently depending on the tissue concerned. In fact, Bermano et al. showed that with
H4 hepatoma cells (Bermano G. et al., 1996), as with H3B and HL-60 myeloid cells
(Baker, R.D. et al., 1993, Chada, S. et al., 1989), culture in medium without a supplement
of sodium selenite led to the cells becoming Se-depleted. After 3 days in such medium
the H4 cells had lost 80% of their cGpx activity. This loss of cGpx activity was
accompanied by a reduction in cGpx mRNA and a smaller reduction in PHGpx activity,
although there was no change in PHGpx mRNA abundance (Bermano G. et al., 1996).
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Figure 2: Overview of Selenoprotein biosynthesis (E. coli as a model)
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Selenium deficiency causes a decrease in the concentrations of most
selenoproteins but selenoprotein P and type I iodothyronine 5'-deiodinase (5'-deiodinase)
are more resistant to this effect than is glutathione peroxidase. It has been shown that
levels of all 3 mRNAs encoding deiodinase, selenoprotein P and Gpx decreases
progressively with time by feeding a selenium-deficient diet to weanling rats for 14.5
weeks. In these experiments, mRNA decreases was correlated to decreases in Gpx
activity and selenoprotein P concentration. These results suggest that synthesis of Gpx
and selenoprotein P is limited to a similar extent at the translational level by the
availability of selenium (Hill, K E. et al. 1992).

1.4- Selenoproteins with known function

1.4.1- Thioredoxin reductase (TrxR)
TrxR catalyzes the NAPDH-dependent reduction of oxidized thioredoxin.
Reduced thioredoxin provides reducing equivalents for processes such as reduction of
ribonucleotides to deoxyribonucleotides by ribonucleotide reductase (Holmgren, A.,
1989) and is also considered a regulator of cellular redox balance (Follmann, H.,
Haberlein, I., 1996), (Powis, G. et al., 1994). TrxR has been the focus of investigations
for several decades but was first identified as a selenoprotein by Tamura and Stadtman in
1996 (Tamura, T, Stadtman, T.C., 1996). TrxR is a FAD-containing disulfide reductase
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that plays an important role in cell proliferation (Holmgren, A., 1985). The important role
of the pool of reduced thioredoxin in DNA synthesis and gene transcription implicates
TrxR as a key enzyme in the control of cell growth. Mammalian forms of TrxR are not
well characterized but rat liver TrxR has been previously isolated as a 116 kDa
homodimer. (Luthman, M., Holmgren, A., 1982). The larger mammalian enzyme is a
selenoprotein containing a SeCys residue in the sequence Cys-SeCys-Gly at the Cterminus of each subunit. (Tamura, T., Stadtman, T.C., 1996, Gladyshev, V.N. et al.,
1996, Liu S.Y. Stadtman, T.C., 1997, Gasdaska, P.Y. et al., 1995).

1.4.2- Glutathione peroxidase (Gpx)
Gpx was the first mammalian selenoprotein identified (Flohe, L. et al., 1973), and
as such is the best characterized mammalian selenoenzyme. In fact, the family of
selenium-dependent Gpx comprises several isoforms of Gpx with differing specificity
and expression patterns in different tissues that have been uncovered in recent years. The
four distinct isoforms are: 1) a classic tetrameric cytosolic cGpx which is the most
ubiquitous; 2) gastrointestinal cytosolic isozyme GIGpx; 3) a secreted form plasma
isozyme pGpx which is released from the kidney into the plasma; and 4) the monomeric
membrane associated phospholipid hydroperoxide PHGpx preferentially expressed in
testis (Brigelius-Flohe, R., 1999). Each of these enzymes catalyzes the thiol-dependent
reduction of hydroperoxides to their corresponding alcohols. The former three are
involved in the neutralization of hydrogen peroxide (H2O2) via the regeneration of
8

glutathione (GSH), their main substrate, with the latter acting on phospholipid
hydroperoxides. Mammalian glutathione peroxidases in the reduced form contain an
ionized selenol that can react with an organic peroxide or H2O2, to form an enzymeselenenic acid (RSeOH) intermediate. PHGpx neutralizes oxidized membrane lipids, has
a broader specificity for cholesterol and phospholipid hydroperoxides, and has been
recently shown to regulate the activity of lipoxygenases (Straif, D. et al., 2000, Werz, O.,
Steinhilber, D., 1996, Ursini, F. et al., 1999, Flohe, L., 1989, Ursini, F. et al., 1995).

1.4.3- Methionine sulfoxide reductase (Msr)
A new selenoprotein identified both by radioisotope labeling and bioinformatic
techniques (Kryukov, G.V. et al., 1999) has been shown to be a form of methionine
sulfoxide reductase (Kryukov, G.V. et al., 2002) and has been termed SelR. Msr proteins
convert free methionine sulfoxide and methionine sulfoxide residues in oxidatively
modified proteins back to methionine in a thioredoxin-dependent manner (Brot, N. et al.,
1982, Lowther, W.T. et al., 2002, Moskovitz, J. et al., 2002). Recent knockout and
expression studies looking solely at the non-selenium dependent forms of these enzymes
underline the important role these enzymes play in aging and oxidative stress. Studies
have shown that the cyclic interconversion of Met and MetO residues of proteins is
involved in several different biological processes such as: 1) an antioxidant mechanism
for the scavenging of ROS; 2) the regulation of enzyme activities; and 3) cell signaling
(Stadtman, E.R. et al., 2003). In the same study, they also postulated that a decrease in
9

Msr activities in brain tissues may be associated with the development of Alzheimer's
disease.

1.4.4- Selenophosphate synthetase (SPS)
E. coli SPS is a 37 kDa enzyme that catalyzes the formation of selenophosphate
(SeP03-), a reactive selenium (Se) donor compound from ATP and selenide and releases
the beta-phosphate as orthophosphate (Leinfelder, W. et al., 1990). SPS has been isolated
from an overproducing E. coli strain and purified (Veres, Z. et al., 1994, Lacourciere
G.M., Stadtman, T., 1999). SPS uses a reduced form of selenium (NaHSe in the in vitro
assay) and ATP to generate selenophosphate. From the gene sequence, E. coli SelD
contains 7 cysteine residues, 2 of which are located at positions 17 and 19 in the sequence
-Gly-Ala-Cys-Gly-Cys-Lys-Ile- (Leinfelder, W. et al., 1990). Mutation in SelD gene
eliminates the ability of E. coli to incorporate selenium into selenoprotein. Inactivation of
the SPS enzyme by alkylation with iodoacetamide indicated that at least one cysteine
residue in the protein is essential for enzyme activity. Based on DNA sequence, a
selenocysteine residue occurs in some eukaryotes and prokaryotes and in at least one of
the human forms (SPS2) (Figure 3).
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Organism

Conserved N-terminal domain sequence

Escherichia coli

LTQYSHGAGCGCKISPKVL

Salmonella typhimurium

LTQYSHGAGCGCKISPKVL

Yersinia pestis CO92

LTQYSHGAGCGCKISPKVL

Haemophilus influenzae

LTQYSHGAGUGCKISPKVL

Homo Sapiens SPS2

LTGFSGMKGUGCKVPQEAL

Homo Sapiens SPS1

LTRFTELKGTGCKVPQDVL

Mus musculus SPS2

LTSFSGMKGUGCKVPQETL

Mus musculus SPS1

LTRFTELKGTGCKVPQDVL

U = selenocysteine
Sequences were derived from DNA sequences in the Genbank database
(NCBI,NIH)

Figure 3: Conserved Proximal dithiol/selenol motif in primary sequence of selected
bacterial and mammalian SPS

This SeCys residue is located proximal to a cysteine in a conserved motif (UXC)
within the N-terminal region of SPS and corresponds to a required cysteine residue in the
E. coli enzyme, based on site-directed mutagenesis (Kim, I.Y. et al., 1992).
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In these mutagenesis studies, these cysteine residues were mutated to serine
residues. The authors tested the biological activities of the wild type and mutant proteins
using E. coli MBO8 (selD-) transformed with plasmids containing the wild type and
mutant selD genes. Their results showed that the plasmid containing the Cys17-mutated
gene failed to complement the selD- mutation in MBO8, whereas the Cys19-mutated gene
was indistinguishable from wild type. The mutant proteins, like the wild type enzyme,
bound to an ATP-agarose matrix, demonstrating that their affinities for ATP were
unimpaired. Selenide-dependent formation of AMP from ATP was abolished by mutation
of Cys17, but the Cys19 mutation had no effect on the ability of the enzyme to catalyze the
reaction. These mutagenesis studies indicated that Cys17 has an essential role in the
catalytic process that leads to the formation of selenophosphate from ATP and selenide.
Analysis of the total genomic sequences of Methanococcus jannaschii and
Haemophilus influenzae (Bult, C.J. et al., 1996), (Fleishmann, R.D. et al., 1995) revealed
that the selD gene in these organisms possesses a TGA codon at the position of the E. coli
Cys-17, indicating the presence of a SeCys residue. Moreover, SeCys-containing variants
also were identified in mouse and human enzymes (Guimaraes, M.J. et al., 1996),
(Wilting, R. et al., 1997). Replacement of the SeCys residue of the mouse enzyme with
cysteine decreased but did not abolish enzyme activity (Kim, I.Y. et al., 1997), whereas
changing Cys-17 of SelD to Ser destroyed catalytic activity (Kim, I.Y., 1992). The
second group of SelD homologs present in human, mouse, and Drosophila share high
sequence similarity with the bacterial SPS but lack a cysteine or SeCys residue in the
position that corresponds to Cys-17 of the E. coli enzyme. The human homolog has a
threonine substitution, and a homolog from Drosophila melanogaster contains an
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arginine (Low, S.C. et al., 1995) (Persson, B.C. et al., 1997). However the role of
selenocysteine in the human SPS2 enzyme catalysis is still not known.
Marla Berry and collaborators (Low, S.C. et al., 1995, Low, S.C. et al., 1995)
cloned and sequenced mouse and human genes exhibiting regions of homology with the
E. coli selenophosphate synthetase (selD) gene. The human gene sequence encoded a
motif GTGCK (residues 28-32) resembling the E. coli 16-20 residue segment except that
Cys-17 was replaced with threonine. Expression of the human gene was shown to
regulate the synthesis of 75Se-labeled 5' deiodinase, providing evidence of the production
of selenophosphate by human SPS1. Especially interesting is the finding that an
analogous gene detected in the mouse embryo at early stages of development contains an
N-terminal sequence region corresponding to the E. coli residue 16-20 segment except
that a selenocysteine residue is encoded in place of the essential Cys-17 residue as shown
in figure 3 (Zlotnik, A. et al., 1995, Guimaraes, M.J. et al., 1995).
SPS represents the first defined step in the specific incorporation of
selenocysteine into selenoproteins, since the transport and reduction of selenium has not
been defined at the molecular level. Although trafficking of selenium to SPS is poorly
understood, recent evidence indicates that a selenium binding protein (Self, W.T. et al,
2004) may be involved in linking transport and reduction of Se to SPS in a bacterial
model system. Previous kinetic studies under strictly anaerobic conditions reported an
apparent Km of 7.3µM for sodium hydrogen selenide (NaHSe) using E.coli SPS (Veres,
Z., 1994). The authors measured the formation of AMP from ATP after separation 14Clabeled nucleotides by thin layer chromatography (TLC). Although NaHSe is the only
known substrate for SPS, it is likely that physiological concentrations of NaHSe do not
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exceed nanomolar levels. Thus, the trafficking of Se to SPS is still a key issue to be
resolved in Se metabolism.

1.5- Arsenic as a carcinogenic metalloid
Industries release quantities of numerous metals and metalloids such as arsenic
(As) into the environment exposing humans to elevated concentrations of these toxic
elements. Inorganic As is also naturally occurring, ubiquitous in the environment in the
form of trivalent (AsIII) as well as pentavalent (AsV) species (Hei, T.K., Filipic, M.,
2004). Unlike selenium, arsenic has no known role in biology. In contrast to selenium,
arsenic has been implicated as a contributing factor in carcinogenesis (Hughes, M. F.,
2002). Biologically, the trivalent sodium arsenite is more toxic than the pentavalent
sodium arsenate (Barrett, J.C. et al., 1989). Chronic exposure to arsenic is associated with
skin, lung, liver and bladder cancers with skin being the major target, (Germolec, D.R. et
al., 1998, Landsdown, A.B., 1995, Phillip, R., 1985), however the biochemical
mechanism of this arsenic-induced carcinogenesis is not well described.
Cultured mammalian cells have provided some possible mechanisms by which
arsenical compounds may exert a carcinogenic activity. Sodium arsenite and sodium
arsenate were observed to induce morphological transformation such as enhanced colonyforming efficiency of Syrian hamster embryo cells in a dose-dependent manner (Lee,
T.C. et al., 1985. The trivalent sodium arsenite was more potent sulfhydryl depleting
agent by oxidation of GSH to GSSG than the pentavalent sodium arsenate (Winski, S.L.,
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Carter, D.E., 1995). A recent study has demonstrated that arsenite treatment of cultured
cells results in the production of reactive oxygen species and a prolonged oxidative stress
correlated with a consistently high level of Heme oxygenase I mRNA (Gabis, K.K. et al.,
1996, Takahashi, S. et al., 1998). DNA microarray studies demonstrated early
upregulation of three different TrxR genes following arsenite treatment (Hamadeh, H.K.
et al., 2002, Rea, M.A. et al., 2003). It is clear from these studies that treatment of
cultured mammalian cells results in oxidative stress, yet the molecular mechanism behind
this oxidative stress is unknown.

1.6- Arsenite interactions with glutathione
Arsenite, the predominant trivalent species of arsenic in the environment, is
known to react with intracellular thiols such as glutathione (GSH) (Scott, N. et al., 1993).
Reactions between GSH and arsenite have been characterized using 1H and 13C NMR.
These investigators followed binding of As to GSH through the thiol group by shifts in
the carbon atom bonded to the sulfhydryl group of the cysteinyl residue, i.e., the CH2
carbon atom and the protons bonded to it. Sodium arsenite, As(III), bound to GSH to
form an As(SG)3 complex in solution as indicated by NMR spectra. The toxicity of
arsenite has been attributed to the inhibition of enzymes with proximal or vicinal thiol
residues, such as the lipoamide-dependent α keto-acid dehydrogenases of the Krebs cycle
(Lin, S. et al., 2001, Gorin, Y., Leseney, A.M., 1997, Cavigelli, M. et al., 1996). More
recently, TrxR has also been shown to be inhibited by trivalent arsenic compounds both
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in vitro and in vivo (Lin, S. et al., 1999, Styblo, M., Thomas, D. J., 1995). However, 50%
inhibition required greater than 100 µM arsenite. Other members of the pyridinenucleotide dependent family of oxidoreductases, such as GSH reductase, have also been
shown to be inhibited by arsenite and other trivalent arsenic species (Styblo, M., Thomas,
D. J., 1995). Each of the pyridine-nucleotide dependent oxidoreductases has conserved
proximal cysteines (and/or selenocysteines) within their active sites. It is presumed that
arsenite is reacting with and/or binding to these sites in the inhibition of these enzymes,
although direct binding studies have not been performed. Arsenite has high affinity to
GSH and free radicals induced by arsenite can oxidize GSH, hence depleting the level of
antioxidant. Arsenic-thiol interactions were investigated by determining changes in rat
blood sulfhydryls after exposure to arsenate, As(V), or arsenite, As(III). (Winski, S.L.,
Carter, D.E., 1995).

1.7- As/Se mutual sparing effect
The first experimental evidence indicating a link between the metabolism of
inorganic arsenic and selenium was reported more than 60 years ago (Moxon, A. L.,
1938) after feeding rats with sodium arsenite (in drinking water) along with seleniferous
grains in order to prevent Se poisoning. In these studies, the poisonous arsenite was
capable of preventing toxic effect of selenium, thus, these metalloid displayed a mutual
sparing effect. Later studies demonstrated that the chronic ingestion of arsenite abolishes
the anticarcinogenic effect of Se in rats ( Ip, C.; Ganther, H. E. 1988), providing a
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potential explanation of the association of cancer with prolonged As intake in humans
(Chen, C.J. et al.; 1988, Wu, M.M. et al., 1989). In fact, several studies showed the link
between high As/Se ratio (lung, blood) and carcinogenesis. (Wester, P.O. et al., 1981;
Wang , C.T. 1996). Research on Blackfoot disease patients proved As to be the major
causative agent of the disease and the authors attributed the decrease of Se to the
antagonistic effect of arsenic (Wang, C.T. et al., 1993). Blackfoot disease (BFD) is a
severe form of peripheral vascular disease, in which the blood vessels in the lower limbs
are severely damaged, resulting eventually in progressive gangrene. This disease has
been limited to certain areas of Taiwan with elevated levels of arsenic.
More recent studies on residents living in an As-contaminated area in Bangladesh
corroborated the previous observation by suggesting that As alters Se metabolism,
increasing Se excretion through bile or feces (Miyazaki, K. et al., 2003).

1.8- Arsenic and Selenium containing thiol conjugates
Previous studies have shown seleno-bis (S-glutathionyl) arsinium ion
[(GS)2AsSe]- to be the major As and Se excretory product in bile of rabbits treated with
arsenite and selenite (Gailer, J. et al., 2002, Gailer, J., 2002). In these studies, the authors
have intravenously injected rabbits with different combinations of the arsenic and
selenium oxo-anions (arsenite + selenate, arsenate + selenite, and arsenate + selenate) and
analyzed the collected bile and whole blood samples by X-ray absorption spectroscopy.
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Only the injection of arsenite and selenate led to the biliary excretion of [(GS)2AsSe]within 25 min. In these studies, the stability of the compound was not addressed.
The antagonism between arsenite and selenite may have its molecular basis in the
formation the arsenic-selenium compound. Previous work on the metabolism of
arsenate(AsV) and selenate in mammals (mice and rabbits) by determination of arsenic
metabolites in plasma and urine after administration of [74As] arsenate revealed that these
compounds are individually reduced in vivo to arsenite (AsIII) (Vahter, M., Envall, J.,
1983, Vahter, M., Marafante, E. 1985) and selenite (Kobayashi, Y. et al., 2001). When As
and Se are co-administered, a mutual inhibition of the individual methylation pathways
occurs and this may be explained by the formation of [(GS)2AsSe]- (Levander, O. A.;
Argrett, L. C., 1969; Hsieh, H. S.; Ganther, H. E., 1975; Zakharyan, R. et al.; 1995).
The biliary excretion of [(GS)2AsSe]- may be especially important in view of the fact that
prolonged exposure to inorganic arsenic in drinking water significantly reduces tissue
selenium concentrations ( Wang, C.T., 1996). Discovery of the As-Se complex may be
used against the pathological effects of inorganic arsenic in drinking water (in
Bangladesh for example) by increasing the daily intake of selenium leading to the
formation and excretion of [(GS)2AsSe]-.
Based on known interactions of As with vicinal dithiols and the fact that
selenophosphate synthetase also contains a proximal cysteine motif (Figure 3), we have
tested the possibility that arsenite and/or (GS)2AsOH (AsIII) would inhibit SPS. In order
to facilitate this kinetic analysis, we have developed a spectrophotometric assay to
analyze the initial rate of selenide-dependent production of inorganic phosphate
(Figure 5) from E. coli SPS. We also determined whether As treatment of cultured cells
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(Hela and HaCaT keratinocyte) would have an effect on the incorporation of Se into
selenoproteins using the radioisotope 75Se. A better understanding of the interrelationship
of arsenic and selenium could lead to a possible mechanism of arsenic-induced
carcinogenicity that may open a door towards an efficient treatment of population
exposed to high levels of arsenic.
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CHAPTER TWO: MATERIALS AND METHODS

2.1- Selenophosphate synthetase spectrophotometric assay

2.1.1- Assay Principle
A coupled assay for the determination of inorganic phosphate (Pi) described by
Webb (Webb, M.R., 1992) was used to follow NaHSe-dependent SPS activity. This
sensitive enzymatic assay was used to monitor the kinetics of phosphate release by SPS
in solution through formation of a chromophoric product. In the presence of inorganic
phosphate (Pi), 2-amino-6-mercapto-7-methylpurine riboside (MESG) is converted by
purine nucleoside phosphorylase (PNP) to ribose 1-phosphate and 2-amino-6-mercapto7-methylpurine.
An increase in absorbance at 365 nm is monitored spectrophotometrically and
proportional to Pi consumption by the MESG/PNP reaction (Figure 4).
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MESG

Figure 4: Enzymatic conversion of 2-amino-6-mercapto-7-methylpurine riboside
(MESG) to ribose 1-phosphate and 2-amino-6-mercapto-7-methylpurine by purine
nucleoside phosphorylase (PNP). The accompanying change in absorption at 365 nm
allows quantitation of inorganic phosphate (Pi) consumed in the reaction.

2.1.2- Synthesis of sodium hydrogen selenide
NaHSe was synthesized as previously described (Klayman, D.L., Griffin, T.S.,
1972). The reagents were purchased from Acros Organics. All the reactions were
performed in an anaerobic chamber (Coy Laboratory Products, Inc. Grass Lake,
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Michigan). Equation (1) summarizes the reaction of sodium borohydride with elemental
Se to yield sodium hydrogen selenide.

4NaBH4 + 2Se + 7H2O

2NaHSe +Na2B4O7+ 14H2 (1)

Aqueous solution of sodium borohydride (1.5 mM) was added drop wise at room
temperature to an aqueous solution of metallic selenium (0.725 mM) in a 2:1 molar ratio.
The reaction was completed within 15 minutes and colorless NaHSe resulted (590 mM
final concentration). NaHSe was separated from residual borate by passage through a
G10 column (30 X 1 cm from Sigma-Aldrich) and stored at room temperature under
anaerobic conditions until used as a selenium substrate for SPS assays.

2.1.3- Spectrophotometric assay procedure
The assay was performed at 37 °C in an anaerobic cuvette (Fisher Scientific) due
to oxygen sensitivity of the NaHSe and the product selenophosphate according to
equation (Figure 5) (Bock, A., Stadtman, T.C., 1988; Kramer, G.F., Ames, B.N. 1988;
Wittwer, A.J., Stadtman, T.C. 1986).

NaHSe +ATP → SePO4 + AMP + Pi
Figure 5: Overall Reaction catalyzed by SPS
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The reaction buffer included 100 mM Tris (ICN Biomedicals), 20 mM KCl
(Fisher Scientific), 4 mM MgCl2 (Alfa Aesar) and the pH was adjusted to 7.2. All the
reagents were degassed in the anaerobic chamber prior to use. The 700 µl reaction
mixture contained: 0.2 mM MESG substrate, 1 U of purine nucleoside phosphorylase
(PNP) (Molecular Probes), 2 mM ATP (Alexis Biochemicals), variable concentrations of
E. coli SPS and NaHSe. The reaction mixture was equilibrated to 37 °C in a sealed
anaerobic cuvette (Fisher Scientific) using a thermostattable cell holder incorporated in
the Agilent 8453 UV-Visible spectroscopy system (Alpha-Omega Technologies, Inc.,
Brielle, New Jersey). A uniform temperature was maintained by circulating water from a
thermostatted water bath through the manifold. The spectrophotometer was first blanked
using previously cited mixture without ATP and NaHSe. A baseline activity reading was
taken prior to the addition of ATP using a gas-tight syringe. The NaHSe-dependent
production of Pi was measured by ascertaining the increase in absorbance at 365 nm as
previously described (Figure 6). For SPS inhibition studies, sodium arsenite was diluted
for each experiment from a 100 mM stock solution and different concentrations (10, 17.5
and 25 µM) added anaerobically before the substrate selenide which was incorporated
last to the reaction cuvette.

23

0.30

0.25

NaHSe

0.20

0.15

0.10

0.05

Ab

ATP

b

0.00

-0.05

36

0

5

10

15

20

25

Time (min)

Figure 6: Representative SPS Assay: NaHSe-dependent production of Pi. The arrows
indicate the times of addition of the reagents.

2.1.4- Synthesis of Seleno-bis (S-glutathionyl) arsinium ion [(GS)2AsSe]All the reactions and purification were performed under anaerobic conditions at room
temperature. NaHSe was previously made for SPS assay.
•

As(OH)3 + 2GSH

•

(GS)2AsOH + NaHSe

(GS)2AsOH + 2H2O
[(GS)2AsSe]- + 2H2O

(GS)2AsOH (0.1 mM) was prepared by mixing aqueous GSH (0.2 M) and sodium
arsenite solution (0.1 mM) in 2:1 molar ratio and the pH adjusted to 7.6. NaHSe and
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(GS)2AsOH were mixed in a 1:1 (V/V) ratio to bring the final pH to 8.5. The compound
was purified by passage through G10 column (30 cm-column) under strictly anaerobic
conditions. An aliquot of each fraction was exposed to the ambient air to allow the
detection of Se-containing eluates. Pure [(GS)2AsSe]- was recovered by pooling the Secontaining fractions after gel filtration. (Gailer, J. et al., 2002)

2.2- Cultivation of Keratinocytes

2.2.1- Culture
A keratinocyte cell line, HaCaT (Kind gift of Dr. Norbert Fusenig, Institute of
Biochemistry, Cancer Research Center, Heidelberg, Germany), was cultured in
Dulbecco’s modification of Eagle’s medium 1X (DMEM) with L-Glutamine and 4.5 g/l
glucose supplemented with 10 % fetal bovine serum (FBS), 10,000 µg/ml streptomycin,
and 10,000 IU/ml penicillin (Mediatech, Inc.). The cells were incubated at 37 °C with
5 % carbon dioxide to maintain proper pH. The culture was collected treating the cells
with 0.05 % EDTA- Dulbecco’s Phosphate Buffered Saline (DPBS) without
calcium/magnesium (Ca/Mg), then trypsin and transferring into a centrifuge tube as
previously described (Fusenig, N.E., 1971).
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2.2.2- Culture in basal medium
Due to the presence of selenoprotein P in the serum along with undefined forms
of Se, we also cultured the keratinocytes in defined keratinocyte medium with LGlutamine and growth supplement (Gibco, Grand Island, New York). These cultures
were routinely acclimated to the defined medium for at least one passage before each
experiment.

2.2.3- Long term arsenite treatment
At 3-4 days post-confluence, the cells were split at a 1:5 ratio and the medium
changed the next day. To the fresh medium was added 0.5 and 1 µM sodium arsenite (in
triplicate) along with untreated control cultures. Images of the cultures were taken daily
using an inverted microscope to document any morphology changes. The cells were then
washed with DMEM then DPBS with Ca/Mg by centrifugation and the cell pellet was
resuspended in lysis buffer for further sonication. Lysis buffer contained 50mM Tricine
pH 8.0, 0.1 mM Benzamidine, 0.5mM EDTA and 1mM DTT.
The crude cell lysate was clarified by centrifugation at 13000 x g for 10 minutes.
This crude cell extract was used for further determination of enzyme activities or
immunoblot analyses of selenoproteins.
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2.2.4- Short term arsenite treatment
At confluency, the cells were treated with 2 µM sodium arsenite for 4 days.
Untreated cells served as controls. Every 24 hours, control and treated cells were
harvested as described in the previous section and the cell pellet stored at -20 °C until
needed for further analysis.

2.2.5- Short term arsenite treatment of cells grown in defined medium
To determine the involvement of other selenoproteins in the FBS as Se source, the
cells were grown in defined keratinocyte medium (Basal medium) for 72 hours, split
(1:2), then treated the next day with 2 and 4 µM sodium arsenite for another 72-hour
period. Every 24 hours, a subset of cultures were harvested and stored at -20°C for
further analysis.

2.2.6- MTT Cell Proliferation Assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay
provides a simple method for determination of cell number using standard microplate
absorbance reader. This assay was developed by Mossman (Mossman, T., 1983) and
involves the conversion of the water soluble MTT (3-(4,5-dimethylthiazol-2-yl)-2,527

diphenyltetrazolium bromide) to an insoluble formazan ( Liu, Y. et al., 1997; Berridge,
M.V., Tan, A.S. 1993; Vistica, D.T. et al., 1991). The formazan is then solubilized, and
the concentration determined by optical density at 570 nm.
Assay Protocol
HaCaT cells were cultured in 96-well plates (0.31 cm2 growth surface, 340 µl
volume) in defined medium which contains 10 nM sodium selenite (ICN Biomedicals,
Inc., Aurora, OH) for 24 hours and treated with increasing concentrations of sodium
arsenite (0, 3, 6, 10, 12, 14 and 16 µM in triplicates) for another 24-hour period. A subset
of cultures was supplemented with 40 nM and 90 nM sodium selenite to reach a final
concentration of 50 and 100 nM.
A 12 mM MTT (Amresco, Solon, OH) stock solution in sterile PBS pH 7.4 was
made and stored at 4°C protected from light (for four weeks maximum). MTT was added
(10 µl) to each well (96-well plate) to obtain a final concentration of 1.2 mM. A negative
control of 10 µl of the MTT stock solution added to 100 µl of medium alone was
included. The culture was then incubated at 37 °C for 2-4 hours. After incubation of the
cells with MTT, as described above, a solution of 10 % SDS- 0.01 M HCl (100 µl) was
added to each well as a solubilizing agent to dissolve the formazan (Carmichael, J. et al.,
1987) and mixed thoroughly with the pipette. The culture was then incubated at 37 °C for
18 hours. The samples were mixed again and absorbance read at 570 nm using a
SpectraMax 190 microplate reader (Molecular Devices Corporation, Sunnyvale, CA) or
Dynex MR (DYNEX Technologies, Inc., Chantilly, VA).
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2.3- Bradford Assay

2.3.1- Principle
The Bradford Assay was used for determining protein content of cell extracts or
purified protein concentrations preparations. The assay is based on the observation that
the absorbance maximum for an acidic solution of Coomassie Brilliant Blue G-250 shifts
from 465 nm to 595 nm when binding to protein occurs. Both hydrophobic and ionic
interactions stabilize the anionic form of the dye, causing a visible color change
(Bradford, M. M. (1976) Anal. Biochem. 72, 248).
Bradford reagent: Coomassie Brilliant Blue G-250 (100 mg) was dissolved in 50
ml 95 % ethanol, added 100 ml 85 % (w/v) phosphoric acid. The solution was diluted to
1 liter when the dye completely dissolved, and filtered through Whatman #1 paper. A
standard curve of absorbance at 595 nm versus protein concentration was routinely
prepared for protein assays using BSA as a standard.
The spectrophotometer was warmed up for 15 min before use and the samples
diluted with distilled water to an estimated concentration of 1 to 20 µg/ml. Standards
containing a range of 1 to 2.5 µg protein (bovine serum albumin) to a volume of 200 µl
were prepared. Dye reagent (1 ml) was added and incubated 5 min. Absorbance at 595
nm was measured.
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2.4- Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
SDS-PAGE was used to analyze the protein content of cell lysates and as the first
step for immunoblot analysis of selenoenzymes. A 12 % polyacrylamide gel was used to
resolve the proteins and 5 % gel to stack the extract in the lanes. The 4X separating gel
buffer consists of 0.4 % SDS, 1.5 M Tris-HCl, pH 8.8. The 4X stacking gel buffer
consists of 0.4 % SDS, 0.5 M Tris-HCl, pH 6.8. Our 10ml separating gel contained 2.5
ml 4X separating buffer, 4.0ml 30 % acrylamide stock solution (29.2 % acrylamide, 3.5
ml distilled water, 100 µl 10 % ammonium persulfate, and 10 µl TEMED. The 5 ml
stacking gel contained 1.25 ml 4X stacking buffer, 0.83 ml (4 %) 30 % acrylamide stock
solution, 2.9 ml distilled water, 50 µl 10 % ammonium persulfate and 5µl TEMED. The
running buffer contained 25 mM Tris-HCl, 192 mM Glycine and 0.1 % w/v SDS. The
samples were denatured by addition of 2X SDS-PAGE sample buffer (4X stacking gel
buffer, 20 % glycerol, 4 % SDS, 31 mg/ml DTT) and the samples were boiled for 5
minutes, followed by a 10-minute cooling at room temperature. Proteins were subjected
to electrophoresis for 55 minutes at 150 volts.

2.5- Western blot analysis
Western blot were used to analyze the level of glutathione peroxidase (Gpx) and
thioredoxin reductase (TrxR) proteins in the control and arsenite-treated samples. Thirty
to 50 µg of protein extract ( varied in alternate experiments) was analyzed using 12 %
SDS-PAGE, and subsequently transferred (transfer buffer 25 mM Tris-HCl, 192 mM
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Glycine, 20 % v/v Methanol) onto a hydrophobic polyvinylidene fluoride (PVDF)
membrane. The transfers were routinely performed overnight at 30 volts for optimal
transfer of protein. The membrane was incubated in a 2 % bovine serum albumin solution
(BSA) in TBS-Tween for 1 hour to block the membrane. The primary antibodies used at
1/1000 dilution were polyclonal sheep anti-Gpx (company) or rabbit anti-TrxR
(Stadtman, T.C., NIH). The secondary antibodies (1/1000 dilution) were rabbit antisheep, and goat anti-rabbit each conjugated with alkaline phosphatase. The required
reagents were Tris buffered saline with Tween-20 (TBS-T ) 20 mM Tris-HCl pH 7.2, 150
mM NaCl, 0.01 % Tween-20), 2 % BSA in TBS-T and phosphatase alkaline buffer (0.1
M Tris, 100 mM NaCl, 5 mM MgCl pH 9.5). We used a chromogenic detection system
with nitro blue tetrazolium (NBT, 5mg/ml of 70 % Dimethyl Formamide, DMF) and 5bromo-4-chloro-3-indolyl phosphate (BCIP, 5 mg/ml of 100 % DMF) in alkaline
phosphatase buffer to visualize the presence of bound secondary antibody.

2.6- Selenium (75Se) labeling of selenoproteins
HaCaT cells were cultured in DMEM with 10 % FBS in the presence of arsenite
(200 nM to 8 µM). The keratinocytes were radiolabeled with 100 µl 75Se
(approximatively 10 µCi) in 10 nM sodium selenite for 8 hours. Cells were then
harvested, lysed by sonication, clarified by centrifugation (13,000 x g) and 28 µg of cell
extract was loaded in each lane (determined by Bradford assay with BSA as standard).
The gel was stained with Coomassie blue G250 for 1hour, then destained for 30-60 min
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with a solution composed of 50 % methanol and 10 % acetic acid. After drying the gel
overnight (DryEase Minigel Drying System from Invitrogen, Carlsbad, CA), and
incubation for 3 days in the phosphor storage cassette, the radiolabeled proteins were
visualized using a Storm 840 phosphorimager (Molecular Dynamics/ Amersham
BioSciences). The storage cassette screen retains energy from beta particles, X-rays, and
gamma rays. Upon laser-induced stimulation, light is emitted from the storage phosphor
screen in proportion to the amount of radioactivity in the sample. 75Se isotope
incorporation was also determined using a Perkin-Elmer 1470 Gamma counter from Life
Sciences and quantitatively compared to total protein concentration to determine the
efficiency of Se incorporation (cpm/µg of extract).

2.7- Sulfur (35S) labeling
HaCaT keratinocytes were grown in 12-well plates (3.66 cm2 growth surface,
6.30 ml volume), and then treated with increasing concentrations of arsenite from
200 nM to 6 µM for 4 hours. Two µl (29 µCi) of
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S (Redivue Pro-Mix 35S, Amersham

BioSciences, San Francisco, CA) in the form of Cys and Met in 2 ml DMEM (low Cys
and Met) was used to label newly synthesized proteins during arsenite treatment. After
the 4-hour period, the cells were harvested, lysed and a crude cell extract made as stated
previously in section 2.2.3. To determine the radioactivity (35S) in each extract, 5 µl of
sample was added to 3.5 ml of Opti-Fluor scintillation liquid (PerkinElmer Life Sciences,
Boston, Massachusetts) and read using a TriCarb 2900TR liquid scintillation analyzer
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(Packard BioScience, Boston, Massachusetts). Equal concentration of protein (1 µg) was
analyzed by SDS-PAGE. The 12 % gel was then dried immediately without staining.
After drying and incubation for 3 days in the phosphor storage cassette, sulfur
incorporation into protein was analyzed by a phosphorimager (Amersham BioSciences).

2.8- Haemophilus inflenzae (H. i.) SPS overexpression
A selenocysteine-containing SPS was overexpressed using E. coli BL21 strain
that contained the plasmid coding for HISPS (pET3aHIselD). The plasmid was obtained
as a generous gift from T.C. Stadtman (NHLBI, NIH, Bethesda, Maryland). Cells were
grown aerobically in 2.8-liter flasks containing Luria broth (10 g tryptone, 5 g yeast
extract, 5 g NaCl /L) supplemented with 0.3 % dextrose, 10 mg/L chloramphenicol and
100 mg/L ampicillin. Flasks were incubated at 37 °C with vigorous shaking (180 rpm)
until the optical density (OD) reached 0.7 at 600 nm. Expression of HISPS was then
induced with Isopropyl-ß-D-thiogalactopyranoside (IPTG) and cultured at room
temperature for 24 hours. OD readings and samples were taken at 2 hour intervals for 6
hours and then overnight. Cells were harvested using a SLA 1500 rotor (Sorvall)
centrifuge, 5,000 rpm at 4 °C for 10 minutes. Cell pellets were washed in buffer A (50
mM Tris, 0.5 mM EDTA, 1 mM DTT), then lysed in lysis buffer (50mM Tricine pH 8,
0.1 mM Benzamidine, 0.5 mM EDTA, 1mM DTT) by sonication and the cell debris
were removed by centrifugation at 13,000 rpm for 20 minutes.
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2.9- Haemophilus inflenzae (H. i.) SPS purification
The purification process was done in 3 steps in the following order: Phenyl
Sepharose chromatography, Diethylaminoethyl Fast Flow anion-exchange
chromatography (DEAE) and then gel filtration chromatography (Sephacryl S-200)
(Amersham BioSciences).
Phenyl Sepharose chromatography
All the solvents and buffers were degassed prior to use. The column was
prewashed with 3 column volumes distilled water, followed by passage of 2 column
volumes of buffer A. The column was then equilibrated with buffer A containing 1.5 mM
ammonium sulfate and the sample loaded. A 300 ml gradient of ammonium sulfate (1.5
mM-0 mM) was made with the PACE gradient maker (Bioworld, Dublin, Ohio) to elute
the bound proteins. After a thorough wash with buffer A, the SPS-containing fractions
were eluted with 4 column volumes of 30 % ethylene glycol (EG) in buffer A. Fractions
(5 ml were collected and the presence of HISPS was assessed by western blot using
polyclonal antibody raised against the E. coli SPS. The fractions containing SPS were
pooled concentrated down to a smaller volume, then dialyzed twice overnight (against 1L
of dialysis buffer) to remove the ethylene glycol before loading on a DEAE column. The
dialysis buffer contained 0.5 mM Tris pH 7.5, 0.5 mM EDTA, 0.1 mM DTT.
DEAE chromatography
The dialyzed pooled sample from phenyl chromatography was then applied to a
pre-equilibrated DEAE column. A 0.0-0.5 M potassium chloride (KCl) gradient was used
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to elute bound proteins. The column was washed with buffer A containing 0.5 M KCl
until no significant protein eluted from the column (by Bradford assay, see section 2.3).
The column was cleared of any remnant protein by passage of 2 M sodium chloride
(NaCl). Fractions (5 ml each) were collected during the 0.0-0.5 M KCl gradient and the
presence of Hi SPS was determined by SDS-PAGE and western blot. The fractions
containing Hi SPS were pooled and concentrated down to a smaller volume. No dialysis
was necessary because the salt concentration in the sample was ideal for the next step of
the purification process.
Gel filtration chromatography
The column was slowly washed overnight with a large volume (2 liters) of
distilled water and equilibrated with buffer A containing 0.3 M KCl for 6 hours. The
sample was then loaded manually onto the column close to the column medium. Once the
solvent entered the column, being careful not to perturb the column, the buffer was then
pumped through the column at a slow rate (approximatively 1.5 ml/min). Fractions were
collected and the purity of HISPS assessed by SDS-PAGE. The sample (110 mg) was
determined to be greater than 98 % pure based on SDS-PAGE analysis (Coomassie Blue
staining). The final concentration was determined by absorbance reading at 280 nm in 6
M Guanidinium, HCl in 25 mM Tris pH 7.8 using the predicted molar extinction
coefficient of 8,400 M-1 cm-1.
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2.10- Sample preparation for X-ray atomic absorption (XAS)
A sample of pure HISPS was prepared for XAS analysis by overnight dialysis
against 50 % glycerol in 50 mM Tris, then concentrated to 35 mg/ml protein. A 625 µM
SPS in 50 % glycerol in 50 mM Tris was sent to Dr. Robert Scott at the Department of
Chemistry, University of Georgia, Athens, Georgia for Se XAS analysis.

2.11- Gpx and TrxR activity assay

2.11.1- TrxR

Thioredoxin Reductase

Thioredoxin-S2 + DTNB

NADPH

TNB + Thioredoxin - (SH)2

DTNB = 5,5'-Dithio-bis(2-Nitrobenzoic Acid)
TNB = 5-Thio-2-Nitrobenzoic Acid
NADPH = Nicotinamide Adenine Dinucleotide Phosphate, Reduced Form

This assay is a continuous spectrophotometric rate determination. Thioredoxin
reductase activity was measured as NADPH-dependent 5,5’-dithio-bis-(2-nitrobenzoic
acid) (DTNB) reduction The one ml assay mixture contained 100 mM potassium
phosphate buffer pH 7.0, 0.2 mM NADPH, 2.5 mM DTNB and 10 mM EDTA. The
spectrophotometer was blanked with the above mixture then the assay started with
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addition of 200 µg of protein extract (Gorlatov, S. N., Stadtman, T. C., 1998). A
spectrum was recorded every 15 seconds for 22 minutes, 2 minutes before addition of the
extract and 20 minutes after to determine the baseline rate of DTNB reduction and
subsequently the NADPH-dependent reduction of DTNB in the presence of cell extract.

2.11.2- Gpx
Gpx activity was determined using a previously described coupled assay with
glutathione reductase with slight modifications (Lawrence, R.A., Burk, R.F., 1976). The
assay buffer contained 100 mM potassium phosphate buffer pH 7.0, 0.2 mM NADPH,
0.1 mM EDTA, 1 mM GSH, 240 mU glutathione reductase, 50 µg of protein extract that
was used to blank the cuvette. The oxidation of NADPH by hydroperoxides was followed
spectrophotometrically at 340 nm after addition of 250 µM hydrogen peroxide (H2O2) to
the reaction mixture. A spectrum was recorded every 15 seconds for 12 min., 2 min.
before addition of H2O2 and 10 minutes after. Initial rate of reduction of hydroperoxides
was determined by monitoring the change in absorbance at 340 nm.
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CHAPTER THREE: RESULTS

3.1- Inhibition of Selenophosphate synthetase
Exposure to arsenic by ingestion of contaminated drinking water is linked to skin, lung,
kidney, liver and bladder cancer. The toxicity of trivalent arsenicals such as arsenite is related to
their high reactivity with vicinal dithiols. Arsenite is known to bind to vicinal sulfhydryl groups
on small compounds such as glutathione (GSH). It was shown that E. coli SPS contains seven
Cys residues and two of them are located at the amino-terminal region forming a CXC motif.
Such motif with vicinal dithiols could represent a binding site for trivalent arsenicals which
makes SPS an interesting selenoprotein to study. In addition, SPS is a key enzyme in the
selenoprotein biosynthesis pathway. SPS catalyzes the activation of selenide into
selenophosphate in the presence of ATP, the first step of the pathway.
To determine if sodium arsenite inhibits SPS activity in vitro with sodium selenide as a
substrate, we have spectrophotometrically followed the effect of arsenite on SPS activity. The
experiment was done under strictly anaerobic conditions. Arsenite does not inhibit the coupled
reaction, as we have determined that up to 100 µM arsenite does not affect PNP reaction with
MESG (data not shown). Addition of arsenite resulted in the inhibition of SPS activity (Figure
7). Figure 7 illustrate that arsenite inhibits the NaHSe-dependent hydrolysis of ATP in a
concentration-dependent manner.
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Figure 7: Initial rate plot of a typical SPS assay with 0, 10, 17.5, 25 µM arsenite. Each point
represents at least three independent enzyme assays.

To determine whether this inhibition is competitive with NaHSe, we analyzed SPS
activity at several concentrations of NaHSe while varying the concentration of arsenite. A
summary of these activities is shown in a double-reciprocal plot of SPS activity versus [NaHSe]
in figure 8. Inhibition of SPS by arsenite is competitive. A plot of the slopes of the lines in figure
8 versus arsenite concentration revealed an apparent Ki of 3 µM. This is roughly half the apparent
Km we have measured for SPS (7.8 µM), demonstrating that arsenite or other trivalent arsenicals
could be relevant inhibitors in vivo.
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Our results are consistent with previous findings (Km of 7.3 µM for NaHSe) using 14CTLC, a different method. (Veres, Z., 1994).
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Figure 8: Double reciprocal plot to analyze the type of inhibition of SPS by arsenite. Each point
represents at least three independent enzyme assays.

Arsenic binds to macromolecules such as glutathione upon entry into the cell (Winski,
S.L, Carter, D.E., 1995).
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Hence, we have tested the possibility that the glutathiolated derivative, (GS)2AsOH being a
trivalent in vivo form of arsenic, acts as SPS inhibitor. As shown on figure 9 (GS)2AsOH also
inhibits SPS in a concentration-dependent manner (10, 25 and 50 µM).
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Figure 9: Plot of Activity (nmoles.min-1.mg-1) versus (GS)2AsOH concentration. SPS was
anaerobically incubated with (GS)2AsOH and the activity was analyzed on a spectrophotometer.
The change in absorbance at 365 nm was recorded. Clearly, (GS)2AsOH, at the concentrations
used, acts as an inhibitor of SPS activity. Each point represents the average of three independent
experiments.
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DNA sequence analysis of SelD gene showed that human SPS 2 contains a SeCys residue
at the N terminal region proximal to a Cys residue (Figure 3. Conserved N-terminal domain
sequence). Since SPS 2 contains a UXC motif, it would be best to test the assays using a human
SPS or the closest form to the human SPS. However, the expression of human SPS1 and SPS2 in
E. coli has been problematic (Tamura, T., unpublished data). Therefore, we attempted to express
and purify a model enzyme, SPS from Haemophilus influenzae which contains a SeCys.

3.2- Attempt to purify active HI SPS
Haemophilus influenzae SPS which contains a SeCys (Figure 3) has been expressed and
purified in a previous study (Lacourciere, G.M., Stadtman T.C., 1999). Because HISPS
resembles the human SPS2, we decided to express and purify this as a model for human SPS2.
HISPS was expressed in E. coli and purified in three steps in the following order: Phenyl
Sepharose chromatography, DEAE Fast Flow anion-exchange chromatography and finally gel
filtration chromatography. During each step of the purification, we used SDS-PAGE analysis and
western blots to determine the fractions to be pooled. Figure 10 shows fractions from the gel
filtration that were pooled to test for SPS activity using the coupled assay.
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Figure 10: SDS-PAGE analysis of fractions collected after gel filtration chromatography. On
lanes 1, 10, purified E.coli SPS was used as a marker. Lanes 3-9 show the degree of purity of
HISPS in each fraction. We obtained 110 mg of about 98 % pure HISPS.

Activity of the purified HI SPS was tested using the same coupled assay that was used to
follow NaHSe-dependent activity of E.coli SPS. We did not detect any activity with the purified
HISPS. To determine whether or not a SeCys residue is present in this purified HISPS, we
prepared the protein (HISPS) for X-ray absorption analysis. XAS analysis carried out in the
laboratory of Dr. Robert Scott (University of Georgia) showed that HISPS preparation did not
contain appreciable quantities of Se. We are unsure why this preparation does not contain
selenium and has no activity.
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We demonstrated that arsenite inhibits SPS and that the inhibition is competitive to
selenide, the substrate. To investigate our hypothesis which states that a possible mechanism of
arsenic toxicity might be the inhibition of selenium bioavailability, we decided to follow
selenium incorporation into selenoproteins.

3.3- Selenium 75 (75Se) labeling
It has been shown that trivalent arsenicals induce the production of ROS in Chinese
Ovary Cells (Wang, T.S. et al., 1996), acute promyelocytic leukemia cells (Jing, Y. et al., 1999),
and human keratinocyte cells (HaCaT) (Shi, H., et al., 2004). Based on our hypothesis, this
increase is due to a decrease of the level of active selenoenzymes in the cell. HaCaT cell line is a
spontaneously transformed human epithelial cell line from adult skin with unlimited growth
potential; it is similar to normal skin cells.
To determine if arsenite has an effect an effect on Se incorporation, we labeled an
arsenite-treated culture of HaCat cells with the radioactive form of selenium (sodium selenite),
75

Se. To trace Se incorporation into selenoprotein, the cells were labeled with 10 µCi 75Se

radioisotope for 8 hours. Cells were then harvested, washed and lysed by sonication as described
in the “Materials and Methods” section. Equal concentrations of cytosolic protein were analyzed
by SDS-PAGE (Figure 11). Figure12 shows a decrease in Se incorporation in a concentrationdependent manner. Arsenite treatment of HaCaT cells prevents incorporation of Se into
selenoproteins in a concentration-dependent manner. The higher the arsenite concentration, the
lower the radioactivity detected, hence, arsenite affects Se incorporation into the cell.
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Based on this finding, we conclude that trivalent arsenicals affect the bioavailability of Se
thus leading to a decrease in selenoproteins at a cellular level. To be sure the observed effects are
specific to selenoproteins, total protein biosynthesis was analyzed.

1

2 3 4 5 6 7 8 9

10 11 12 13 14 15 16 17 18

Figure 11: SDS-PAGE of 75 Selenium (75Se-Selenite) radiolabeled keratinocytes treated with
sodium arsenite. The keratinocytes were treated with increasing concentrations of arsenite from
200nM to 6µM for 8 hours. Protein extracts were resolved on 12% SDS-PAGE and the labeled
proteins were analyzed using a phosphorimager. Lanes 1, 2, 10, 11: controls. Lanes 3, 4: 200 nM
Arsenite. Lanes 5, 6: 500 nM Arsenite. Lanes 7, 8: 1 µM Arsenite. Lanes 9, 12: 2 µM Arsenite.
Lanes13, 14: 4µM Arsenite. Lanes15, 16: 6µM Arsenite. Lanes17, 18: 8 µM Arsenite
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Figure 12: Arsenite treatment prevents selenium incorporation into selenoproteins. The level of
radioisotope Se per microgram of cell protein was determined using a Perkin Elmer gamma
counter.
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3.4- Arsenite treatment of keratinocytes does not affect total protein synthesis
Arsenite treatment of HaCaT cell culture lead to a decrease in the incorporation of Se into
selenoproteins. To determine whether the effect of arsenite on HaCat cells is specific to Se
incorporation or extended to total protein synthesis, we treated the cells with different
concentrations of arsenite and radiolabeled them with Sulfur 35 mixture of methionine and
cysteine (35S) for 8 hours to follow new protein synthesis. Cells were harvested and lysed by
sonication. As indicated by the figure 13 and the graph on figure 14, arsenite has no effect on
total protein synthesis. This confirms that the effect of arsenite is specific to incorporation of Se
into selenoproteins. Although good labeling of cellular proteins was demonstrated using 35S-MetCys mix, we also determine whether arsenite was affecting proliferation of the cells under these
conditions.
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Figure 13: SDS-PAGE after 35 Sulfur (35S) labeling of HaCaT keratinocytes. The keratinocytes
were treated with increasing concentrations of arsenite from 200 nM to 6 µM for 4 hours. Newly
synthesized proteins were labeled during arsenite treatment by 35S methionine/cysteine. Protein
extracts were resolved on 12% SDS-PAGE and the gel was developed using a phosphorimager.
Lane1: control - No arsenite added. Lane 2: 200 nM Arsenite. Lane 3: 500 nM Arsenite. Lane 4:
1 µM Arsenite. Lane 5: 2 µM Arsenite. Lane 6: 4 µM Arsenite. Lane7: 6 µM Arsenite
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Figure 14: Measure of Sulfur incorporated into Met/Cys during new protein synthesis. HaCaT
culture was labeled with 35S, and then treated with increasing concentrations of sodium arsenite.
The cpm/µg of protein was determined using liquid scintillation.
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3.5- Arsenite does not affect keratinocyte proliferation
The previous experiments showed that treatment of HaCaT cells using micromolar
concentrations of arsenite for a relatively short period of time does not affect protein synthesis.
To confirm the viability of the keratinocytes in the presence of arsenite at these
concentrations (up to 16 µM), we did an MTT cell proliferation assay. The keratinocytes (4000
cells per well cultured as a monolayer) were incubated with arsenite for 24 hours prior to MTT
treatment. The results presented in figure 15 show a slight decrease in proliferation with 3 and
6 µM arsenite followed by a recovery with 12 µM. At 14 µM, the cell growth becomes stable.
Overall, the cell proliferation was not significantly affected by the concentrations of arsenite
used.
In conclusion, these labeling experiments and cell proliferation assay confirmed that
although arsenite does not affect keratinocytes proliferation in DMEM, it inhibits incorporation
of radiolabeled selenium. As a control then we decided to grow the cells in defined keratinocyte
medium and test the proliferation rate upon treatment with arsenite.
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Figure 15: MTT Cell Proliferation Assay in DMEM. The keratinocytes seeded at 4000 cells per
well were cultured in a 96-well plate for 24 hours and subsequently exposed to increasing
concentrations of sodium arsenite for an additional 24 hours. After addition of MTT (4 hours
incubation), followed by a solution of SDS-HCl for an overnight incubation, the absorbance was
read at 570 nm.
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In DMEM supplemented with serum, other sources of selenium such as selenoprotein P
are available to the cell whereas in the defined keratinocyte medium, only 10 nM of sodium
selenite is present. The composition of this defined medium will allow us to control the Se
supply to the cell in order to detect any effect of higher concentrations of Se in an arsenitetreated keratinocyte culture. To determine the effect of selenite on the keratinocytes proliferation,
the cells were grown in defined medium. A subculture was supplemented with 50 nM and
100 nM sodium selenite for 24 hours before exposure to the same concentrations of arsenite as
reported above. Clearly, arsenite slows cell growth in defined medium as shown by figure 16A.
Here the proliferation was partially recovered after addition of 50 nM selenite (Figure 16B) and
completely with 100 nM (Figure 16C).
Using a defined keratinocyte medium with known concentrations of available selenite,
our results showed that with certain concentrations (up to 100 nM), the effect of arsenite is
reversed.
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Figure 16: Effect of arsenite on cell proliferation. The keratinocytes were grown in defined
medium containing 10, 50 and 100 nM sodium selenite for 24 hours and then treated with
increasing concentrations of sodium arsenite for an additional 24-hour period. After addition of
MTT and SDS-HCl the absorbance was read at 570 nm. The percent cell proliferation was
calculated based on the untreated (no arsenite) sample. With 50 and 100 nM selenite, there is a
protective effect of selenite against arsenite.
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3.6- Long term arsenite treatment of HaCaT with low levels of sodium arsenite
Epidemiological studies have shown that chronic exposure to arsenic contributes to skin,
lung, and bladder cancer (Smith, A.H., 1998, Schwartz, R.A., 1997, Yeh, S., 1973). There is a
link between high levels of arsenite in drinking water and cancer. Also, studies demonstrated
high As/Se ratio in Black-Foot Disease patients (Wang, C.T., 1993). Glutathione peroxidase
functions to neutralize peroxides and oxidized membrane lipids. Thioredoxin reductase is a key
enzyme in the control of cell proliferation and redox balance. Thus active Gpx and TrxR are
essential to the cell’s defense against reactive oxygen species. To mimic the long term exposure
to trivalent arsenicals using a cell culture model, we cultured HaCaT cells in DMEM
continuously for 6 weeks in the constant presence of sodium arsenite and then determined the
effect of arsenite on the cells. After 6 weeks of cell culture (4 passages) without arsenite and with
0.5 and 1 µM arsenite the cells were harvested and disrupted by sonication. The cell extract was
clarified by centrifugation. The protein extract was then tested for Gpx and TrxR level by
western blot and enzyme activity by spectrophotometry.
The long term arsenite treatment under our conditions did not show any morphological
effects on the cells (Figure 17). The western blots show no change in the levels of Gpx and TrxR
levels as presented on figure 18. Glutathione peroxidase and thioredoxin reductase, two
important antioxidant selenoproteins in the cell extract were tested for activity. The activity
assays confirmed the constant level of protein previously observed on figure 18. There was no
significant change of the enzymes activity over time (Figures 19, 20).
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Figure 17: HaCaT treated with 0.5 and 1 µM sodium arsenite after six weeks and four passages.
These concentrations do not appear toxic to the cells.

55

A

TrxR

A1

A2

A3

TrxR

Gpx A1

A2

A3

B1

B2

B3

C1

C2

C3

B

Gpx

B1

B2

B3

C1

C2

C3

Figure 18: Immunoblot analyses of TrxR (A) and Gpx (B) levels after long term exposure (6
weeks) of keratinocytes (HaCaT) to 0.5 and 1 µM of sodium arsenite. A1-3: Control- No
arsenite. B1-3: 0.5 µM of sodium arsenite. C1-3: 1 µM of sodium arsenite
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Figure 19: Gpx Activity Assay on long term arsenite-treated HaCaT culture. The cells were
treated with 0.5 and 1 µM of sodium arsenite for 6 weeks (4 Passages) and then harvested. The
cell extract was used (50 µg) to test Gpx activity by spectrophotometry. The change in
absorbance at 340 nm was recorded and the activity calculated. A long term arsenite treatment
does not affect Gpx activity.
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Figure 20: TrxR Activity Assay on long term arsenite-treated HaCaT culture. The keratinocytes
were treated with 0.5 and 1 µM of sodium arsenite for 6 weeks (4 Passages) and then harvested.
The cell extract was used (200 µg) to test trxR activity by spectrophotometry. The change in
absorbance at 340 nm was recorded and the activity calculated. TrxR activity decreased with
1 µM the first 2 weeks of culture, then with 0.5 µM the following weeks to end up increasing at
the last week of culture.
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In summary, our results showed that arsenite induced no morphological changes of the
keratinocytes after continuous culture in arsenite-containing medium. Also, arsenite did not
affect Gpx and TrxR at the protein level as well as the activity level.
In DMEM supplemented with fetal bovine serum, several selenium sources are available
to the cell. The keratinocytes might be using an alternate pathway that consumes a different
selenium source to produce normal level of selenoproteins. This led us to investigate whether or
not higher concentrations of arsenite for a shorter period of time will affect HaCaT cells and the
selenoproteins level.

3.7- Short term arsenite treatment in DMEM
To determine if higher concentrations have a more significant effect on selenoproteins,
we cultured and treated the keratinocytes with 2 µM arsenite in DMEM for 96 hours. At each 24time point, we harvested untreated and treated cells. After 4 days, we analyzed Gpx and TrxR
levels by western blot. Figure 21 demonstrates that short term arsenite treatment of keratinocytes
has still no effect on Gpx and TrxR levels.
Glutathione peroxidase and thioredoxin reductase activity assay also did not show any
change compared to the untreated control cells (Figure 22). Although there is a downward trend
of Gpx activity at day 2, the decrease is not significant. Overall short term arsenite treatment
does not affect Gpx activity. Hence, we decided to control and limit the Se source by using a
defined keratinocyte medium.
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Figure 21: Analyses of Gpx (A) and TrxR (B) levels after short term exposure (4 days) of
keratinocytes (HaCaT) to 2 µM of sodium arsenite. Protein extracts were resolved on 12% SDSPAGE and analyzed by immunoblot using Gpx and TrxR antibodies. Arsenite treatment had no
effect on Gpx and TrxR levels under the studied conditions. C1-4: Control- No arsenite. D1-4:
2µM sodium arsenite. D1: After 24 hours. D2: After 48 hours. D3: After 72 hours. D4: After 96
hours.
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Figure 22: Gpx Activity Assay on short term arsenite-treated HaCaT culture. The keratinocytes
were grown in DMEM-10 % FBS then treated with 2 µM of sodium arsenite for four days and
then harvested. The cell extract was used (50 µg) to test Gpx activity by spectrophotometry. The
change in absorbance at 340 nm was recorded and the activity calculated.
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3.8- Short term arsenite treatment in defined keratinocyte medium
The keratinocytes have, in DMEM, all the nutrients necessary to grow. In consequence,
the cells might use an alternate selenium supply present in serum. The Se depletion due to
arsenite treatment seen in radioisotope labeling may be compensated by selenoprotein P in the
serum, and this may bypass the effect of arsenicals.
To rule out the involvement of selenoprotein P in the FBS as a selenium source, a basal
serum-free medium with trace of sodium selenite (10 nM) was used to conduct another short
term experiment with 2 µM of arsenite or 4 µM for 72 hours.
Our results presented in figure 23 showed that no change occurred in the cell morphology
or cell density during the three-day treatment with 2 µM of arsenite. The western blot analysis
(Figure 24) confirmed the results by showing steady Gpx and TrxR levels. This led us to increase
the concentration of arsenite to 4 µM in the culture.
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Figure 23: Keratinocytes culture in defined medium. The cells were treated with 2 µM sodium
arsenite for 3 days with no change in cell morphology and cell density.
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Figure 24: Analyses of Gpx (A) and TrxR (B) levels after short term arsenite treatment. The
keratinocytes (HaCaT) were cultured in defined medium, and then exposed to sodium arsenite
for 3 days. Protein extracts were resolved on 12% SDS-PAGE and analyzed by immunoblot
using Gpx and TrxR antibodies. C1-2: Control- No arsenite. D1-3: 2 µM sodium arsenite. D1:
After 24 hours. D2: After 48 hours. D3: After 72 hours.
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3.9- Short term arsenite treatment in defined medium- 4 µM arsenite
Four micromolar arsenite would not be considered a physiologically relevant
concentration but we decided to use such amount in order to trigger enough cell response to
study the effect of arsenite on HaCaT.
Our results showed no change in cell culture (Figure 25) which was confirmed by the
western blot analysis of two proteins marker of oxidative stress, Gpx and TrxR. Their level
stayed steady through the whole experiment (72 hours) (Figure 26). Also, 4 µM of sodium
arsenite did not generate any significant change of Gpx activity over 72 hours (Figure 27).
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Figure 25: Keratinocytes culture in defined medium. The cells were treated with 4 µM sodium
arsenite for 3 days with no change in cell morphology and cell density.
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Figure 26: Western Blot analyses of Gpx (A) and TrxR (B) levels after short term arsenite
treatment (4 µM). The keratinocytes (HaCaT) were cultured in defined medium, and then
exposed to sodium arsenite for 3 days. C: Control- No arsenite. D1-3: 4µM sodium arsenite. D1:
After 24 hours. D2: After 48 hours. D3: After 72 hours. M: Protein marker
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Figure 27: Gpx Activity Assay on short term arsenite-treated HaCaT culture. The keratinocytes
were grown in defined medium then treated with 4 µM of sodium arsenite for four days and then
harvested. Fifty µg of the cell extract was used to test Gpx activity. The change in absorbance at
340 nm was recorded and the activity calculated as indicated in the “Materials and Methods”
section.
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CHAPTER FOUR: DISCUSSION

4.1-Spectrophotometric assay for SPS

Inorganic selenium is inserted into proteins as the rare 21st amino acid selenocysteine
that is essential for the catalytic function of selenoenzymes. It has been shown that selenium is
required in several mammalian enzymes with roles in defense against reactive oxidative species
(Carlson, B.A., et al., 2004). Selenoproteins such as Gpx, TrxR and SPS with known enzymatic
functions contain selenocysteine in their catalytic center (Tamura, T. , Stadtman, T. C., 1996,
(Arner, E. S., Holmgren, A., 2000, Lee, S. R. et al., 2000, Flohe, L. et al, 1973, Brigelius-Flohe,
R., 1999, Chambers, I. et al. 1986, Kryukov, G. V. et al. 2002). Selenoproteins incorporate
SeCys cotranslationnally into the polypeptide chain by a complex mechanism (Low, S.C. et al.,
1996) that is only recently being better understood.
SPS is required for the synthesis of selenoproteins in both prokaryotes and eukaryotes.
SPS uses a reduced form of selenium (NaHSe in the in vitro assay) and ATP to generate
selenophosphate. Previous assays for SPS (Veres, Z., et al, 1992) were hindered by the use of
[14C] ATP and thin layer chromatography (TLC). The SPS assay is a sensitive coupled
enzymatic assay described by Webb (Webb, M.R., 1992) for detecting inorganic phosphate and
to monitor the kinetics of phosphate release by selenophosphate synthetase in solution through
formation of a chromophoric product. We have incorporated this coupled assay to study the
kinetics of SPS. The reagent used in this assay are easily oxidized by air, hence the importance
of working under strictly anaerobic conditions. Veres’s group findings corroborated the above
assertion. In their study of SPS activity, they were able to lower the Km for NaHSe from 46 µM
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to 7.3 µM by maintaining strictly anaerobic conditions (Veres, Z., et al, 1994). [14C] ATP TLC
assay measured the selenide-dependent formation of AMP from ATP after separation of 14C
labeled nucleotides by TLC and required prolonged incubation time and higher levels of enzyme,
hence the importance of developing an improved and sensitive spectrophotometric assay. The
improvement of the method is based on the ability to measure initial rates (V0) more easily.
Using this coupled assay in our study, we have determined the apparent Km value for
NaHSe as 7.8 µM. This is similar to previously reported value using a different method. Our
spectrophotometric assay has proven to be more useful for initial rate analysis and may lead to a
better understanding of other SPS enzymes such as human SPS 1 and 2 in future studies.

4.2-Arsenite inhibits SPS
Arsenic has been implicated as a contributing factor in carcinogenesis (Hughes, M. F., 2002).
Biologically, the trivalent sodium arsenite is more carcinogenic than the pentavalent form
sodium arsenate (Barrett, J.C. et al., 1989). Cultured mammalian cells have provided some
possible mechanisms by which arsenic and arsenical compounds may exert a carcinogenic
activity. Based on known interactions of As with vicinal dithiols and the fact that
selenophosphate synthetase also contains a proximal cysteine motif (Figure 3), we have tested
the possibility that arsenite and/or (GS)2AsOH (AsIII) would inhibit SPS.
Arsenite, a trivalent arsenical known to bind to vicinal and proximal dithiols was found to
inhibit E. coli SPS. Amino acid substitutions in a conserved N-terminal region by Kim et al.
using site-directed mutagenesis have proven that Cys-17 is vital to the enzyme activity. They
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reported a complete loss of SPS catalytic activity when Cys 17 and 19 were substituted to Ser
residues (Kim, I.Y. et al., 1993). Although the structure of SPS has not been elucidated yet,
based on sequence homology, Cys 17 and 19 are likely to be proximal in 3-dimensional space.
Our study has shown that sodium arsenite clearly inhibits SPS activity in a concentrationdependent manner (Figure 7). Kinetic analysis revealed a competitive inhibition with NaHSe
with an apparent Ki of 3 µM likely involving Cys 17 and 19. Since the proximal cysteine motif
has been previously postulated to be involved in selenium binding during catalysis, it seems
likely that arsenite is also binding to this motif. The present results give support to previous ones
suggesting Se binding to the proximal cysteine motif in the conserved N-terminal region. In the
light of our results, it is possible that a decrease in selenoprotein synthesis due to a decrease in
SPS activity might be a molecular mechanism for arsenic-induced carcinogenesis. This
hypothesis led us to the next series of experiments in a cell culture model system.

4.3-Se incorporation into selenoprotein inhibited by arsenite
To determine whether arsenite has an effect on Se incorporation in vivo, we radiolabeled
an arsenite-treated culture of HaCat cells with 75Se. Our results showed a decrease in Se
incorporation (Figure 11) in a concentration-dependent manner after exposure to arsenite. The
higher the concentration of arsenite, the lower the Se incorporated into the cells suggesting that
arsenite may be decreasing selenium bioavailability. New selenoproteins synthesis is affected by
arsenite. Such observation has been reported for the first might be due to the inhibitory effect of
trivalent arsenical on SPS. Another possibility is the formation of As-Se bound compound in
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vivo. In fact, previous studies in rabbit have shown that co-injection of As and Se results in the
formation of [(GS)2AsSe]- which is excreted from the bile (Gailer, J. et al., 2002, Gailer, J.,
2002).
Since Se incorporation was affected by arsenite, we decided to determine whether this
effect is specific to selenoprotein synthesis or not. We labeled the keratinocytes with 35S
radioisotope in order to follow total protein synthesis. We were able to show that, under our
experimental conditions, sodium arsenite effect is limited to Se incorporation and does not
extend to total protein synthesis. This is consistent with our in vitro studies where arsenite
directly inhibits SPS.

4.4-Keratinocytes exposure to arsenite
SPS is inhibited in vitro by arsenite and there is a decrease in new selenoprotein
synthesis. To investigate the effects of arsenite for a short period of time, we cultured HaCaT
cells for 3 days. Western blots analysis showed a steady level of Gpx and TrxR before and after
exposure to 2 µM arsenite. When we analyzed the activity of Gpx and TrxR, we still did not see
any effect. The enzymes activity was constantly normal. This led us to extend the period of
exposure to arsenite.
Based on the lack of effect with the short term exposure, we cultured the HaCaT cells in
DMEM for 6weeks with 0.5 and 1 µM arsenite, 4 passages. Higher concentration (4 µM) killed
the cells after 2 weeks. In this study, although the cells survived, we were not able to detect any
change in Gpx and TrxR levels or activities. Also, concentrations up to 16 µM of arsenite did not
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affect the cell proliferation rate for short periods of time (less than 48 hours). The keratinocytes
are resistant to even long term exposure to arsenite which is in contradiction with our labeling
experiments and in vitro study.
From these results, it is possible that arsenite inhibition is overcome by the cells using an
alternate selenium source present in the medium. Hence, we decided to culture the
keratinocytes in a defined basal medium.

4.5-Keratinocytes culture in defined medium
In DMEM supplemented with serum, other sources of selenium are available to the cells.
To control the Se supply, we cultured the HaCaT cells in defined medium which contains only
one form of Se and at low level. The cells are then treated with 2 and 4 µM arsenite for 3 days.
Arsenite affected the cell proliferation rate in defined medium but failed to generate any change
at the protein level as well as enzyme activity level for Gpx and TrxR.
These initial studies in defined medium have yet to show an effect on TrxR and Gpx
levels, however these cells were not transitioned into defined medium, so further study is needed
under these conditions.
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CHAPTER FIVE: CONCLUSION
In conclusion, in this study we have demonstrated that, in vitro, arsenite inhibits
selenophosphate synthetase by competition with the substrate, sodium hydrogen selenide. We
also observed a decrease in Se incorporation proportional to the increase in arsenite
concentration; yet, we couldn’t detect any correlation between Se incorporation and levels and
activity of two selenoproteins essential in defense against oxidative damage (Gpx, TrxR). It has
been proven that oxidative damage occurs after exposure to arsenicals. Our results might suggest
the existence of a secondary pathway that would counteract the inhibitory effects of arsenite by
incorporating into the cell a different form of selenium whenever the primary form of choice is
depleted. In consequence, our revised hypothesis is that arsenic only affects certain selenium
compounds.
Studies to elucidate a possible secondary pathway of selenoprotein biosynthesis are
ongoing and will allow to better understand the molecular mechanism of arsenic-induced
carcinogenesis in the future.
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